Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Martin Felices, PhD, Dhifaf Sarhan, PhD, Ludwig Brandt, Karolin Guldevall, Ron McElmurry, Alexander Lenvik, Sami Chu, Jakub Tolar, MD PhD, Elizabeth Taras, Stephen R Spellman, MS, Erica D. Warlick, MD, Michael R. Verneris, MD, Sarah Cooley, MD, Daniel Weisdorf, MD, Bruce R. Blazar, MD, Bjorn Onfelt, PhD, Dan Vallera, PhD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 4291.

https://doi.org/10.1182/blood.V128.22.4291.4291

Published: 2016

Journal Articles

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

Martin Felices, PhD, Alexander Lenvik, Sami Chu, Ron McElmurry, Sarah Cooley, MD, Jakub Tolar, MD PhD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2016) 128 (22): 551.

https://doi.org/10.1182/blood.V128.22.551.551

Published: 2016

Journal Articles

FANCN Hypomorphic Mutation Retains BRCA1 Binding Domain

Elizabeth Thompson, MS, Jakub Tolar, MD PhD, Eric A. Hendrickson, PhD

Blood (2016) 128 (22): 2676.

https://doi.org/10.1182/blood.V128.22.2676.2676

Published: 2016

Journal Articles

Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing

Mark J. Osborn, PhD, Beau R Webber, PhD, Friederike Knipping, Cara-lin Lonetree, Anthony DeFeo, Amber McElroy, Colby Starker, PhD, Richard Gabriel, Sarah Merkel, Keli L. Hippen, PhD, Daniel Voytas, PhD, Christof von Kalle, MD, Manfred Schmidt, PhD, Jeffrey S. Miller, MD, Jordan Jarjour, PhD, Alexander Astrakhan, PhD, Andrew M Scharenberg, MD, Jakub Tolar, MD, PhD, Bruce R. Blazar, MD

Blood (2015) 126 (23): 2045.

https://doi.org/10.1182/blood.V126.23.2045.2045

Published: 2015

Journal Articles

Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion

Jeffrey S. Miller, MD, Martin Felice, Ron McElmurry, Valerie McCullar, Xianzheng Zhou, Jakub Tolar, MD PhD, Joerg Uwe Schmohl, Angela Panoskaltsis-Mortari, PhD, Bin Zhang, Elizabeth Taras, Michael R. Verneris, MD, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Dan Vallera, PhD

Blood (2015) 126 (23): 232.

https://doi.org/10.1182/blood.V126.23.232.232

Published: 2015

Journal Articles

Outcomes after Donor Lymphocyte Infusion for Insufficient Donor Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders

Carter Biewen, BA, Angela R Smith, MD MS, Jakub Tolar, MD, PhD, Weston P Miller, IV, MD

Blood (2015) 126 (23): 1969.

https://doi.org/10.1182/blood.V126.23.1969.1969

Published: 2015

Journal Articles

Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jakub Tolar, MD, PhD, John A McGrath, MD, Mark J. Osborn, PhD, Douglas R Keene, BS, Kristen Hook, MD, Maria Hordinsky, MD, David Woodley, MD, Mei Chen, PhD, Alain Hovnanian, MD PhD, Katsuto Tamai, MD PhD, Bruce R. Blazar, MD, John E Wagner, MD

Blood (2015) 126 (23): 402.

https://doi.org/10.1182/blood.V126.23.402.402

Published: 2015

Journal Articles

Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Julie A. Ross, PhD, Jakub Tolar, MD PhD, Logan G. Spector, PhD, Todd E. Defor, MS, Troy C. Lund, MDPhD, Daniel J. Weisdorf, MD, Anthony J. Hooten, B.S., Bharat Thyagarajan, MD PhD, Erica Langer, BS, Michelle K. Gleason, PhD, John E Wagner, MD, Kimberly Robien, PhD RD, Michael R. Verneris, MD

Blood (2014) 124 (21): 683.

https://doi.org/10.1182/blood.V124.21.683.683

Published: 2014

Journal Articles

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Paolo Anderlini, MD, Juan Wu, MS, H. Joachim Deeg, MD, Iris Gersten, MS, Marian Ewell, ScD, Jakub Tolar, MD PhD, Joseph H. Antin, MD, Sally Arai, MD, Mitchell E. Horwitz, MD, John M. McCarty, MD, Ryotaro Nakamura, MD, Michael A. Pulsipher, MD, Roberta H. Adams, MD, Eric Leifer, PhD, Shelly L Carter, ScD, Nancy L DiFronzo, PhD, Mary M. Horowitz, MD MS, Dennis L. Confer, MD, Mary Eapen, MBBS, MS

Blood (2014) 124 (21): 541.

https://doi.org/10.1182/blood.V124.21.541.541

Published: 2014

Journal Articles

Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2

Jakub Tolar, MD, PhD, Julie Curtsinger, PhD, Ron McElmurry, Valarie McCullar, Michael R. Verneris, MD, Frits van Rhee, MD, PhD, Natalia Lapteva, Cliona M Rooney, PhD, John E. Wagner, MD, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 346.

https://doi.org/10.1182/blood.V120.21.346.346

Published: 2012

Journal Articles

Education and Cytokine Receptor Balance Play a Critical Role in Long Term Survival of the Most Differentiated Natural Killer (NK) Cells.

Martin Felices, PhD, Todd Lenvik, Dave Ankarlo, Julie Curtsinger, PhD, Jakub Tolar, MD, PhD, Bruce R. Blazar, MD, Stephen Anderson, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 2148.

https://doi.org/10.1182/blood.V120.21.2148.2148

Published: 2012

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes

Jakub Tolar, MD, PhD, John A. McGrath, MD, FRCP, Mark J. Osborn, PhD, Kristen P. Hook, MD, Douglas R. Keene, BS, Maria K. Hordinsky, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2012) 120 (21): 965.

https://doi.org/10.1182/blood.V120.21.965.965

Published: 2012

Journal Articles

DNA Methylation Profile of Runx1 Regulatory Regions Is Correlated with Transition From Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo

Beau Webber, Michelina Iacovino, Michael Kyba, PhD, Bruce R. Blazar, MD, Jakub Tolar, MD, PhD

Blood (2011) 118 (21): 389.

https://doi.org/10.1182/blood.V118.21.389.389

Published: 2011

Journal Articles

Dyskeratosis Congenita: Evaluation of Immune Status and Hematopoietic Stem Cell Transplantation. A Literature and EBMT Data Base Survey of 75 Patients,

Elisabeth T Korthof, MD, Judith Van der Zalm, med. student, Martine F Raphael, MD, Dorine Bresters, MD, PhD, Jakub Tolar, MD, PhD, Mahmoud Aljurf, MD, Paul Veys, MD MRCP FRCPath, Rosi Oneto, Andrea Bacigalupo, MD, Christina Peters, MD, Bobby Gaspar, MD, Carlo Dufour, MD, Judith C. W. Marsh, Prof MD PhD

Blood (2011) 118 (21): 4144.

https://doi.org/10.1182/blood.V118.21.4144.4144

Published: 2011

Journal Articles

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Jakub Tolar, MD, PhD, H. Joachim Deeg, M.D., Sally Arai, MD, Mitchell Horwitz, MD, Joseph H. Antin, MD, John M. McCarty, MD, Roberta H. Adams, MD, Mary Eapen, MBBS, Marian Ewell, ScD, Eric Leifer, PhD, Iris Gersten, MS, Shelly L Carter, ScD, Mary M. Horowitz, MD, Dennis L Confer, MD, Ryotaro Nakamura, MD, Michael Pulsipher, MD, Nancy L DiFronzo, PhD, Paolo Anderlini, MD

Blood (2011) 118 (21): 3009.

https://doi.org/10.1182/blood.V118.21.3009.3009

Published: 2011

Journal Articles

Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13

Steven L Highfill, PhD, Paulo Rodriguez, PhD, Qing Zhou, PhD, Christine A Goetz, PhD, Rachelle Veenstra, Patricia A Taylor, DVM, Angela Panoskaltsis-Mortari, PhD, Jonathan Serody, MD, David Munn, Jakub Tolar, MD, PhD, Augusto C Ochoa, MD, Bruce R. Blazar, MD

Blood (2010) 116 (21): 241.

https://doi.org/10.1182/blood.V116.21.241.241

Published: 2010

Journal Articles

Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy: A Modern, Single-Institution Experience

Weston P Miller, IV, MD, Steven Rothman, MD, David Nascene, MD, Teresa Kivisto, RN, Todd Defor, Troy Lund, MD, PhD, Jakub Tolar, MD, PhD, Paul Orchard, MD

Blood (2010) 116 (21): 3543.

https://doi.org/10.1182/blood.V116.21.3543.3543

Published: 2010

Journal Articles

Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC)

Mary Eapen, MBBS, Jennifer LeRademacher, PhD, H. Joachim Deeg, Joseph H. Antin, MD, Richard Champlin, Jeanette Carreras, MPH, Joseph W. Fay, MD, Jakob R. Passweg, MD, MS, Jakub Tolar, MD, PhD, Judith C. W. Marsh, MD, Mary M. Horowitz, MD, MS

Blood (2010) 116 (21): 531.

https://doi.org/10.1182/blood.V116.21.531.531

Published: 2010

Journal Articles

“Tasting the Microenvironment”: Human Bone Marrow Stromal Cells Have Microenvironment Chemosensory Capacity Via Taste Receptor Expression

Troy Lund, MD, PhD, Diane Lidke, PhD, Amanda Kobs, Bruce R. Blazar, MD, Jakub Tolar, MD, PhD

Blood (2010) 116 (21): 938.

https://doi.org/10.1182/blood.V116.21.938.938

Published: 2010

Journal Articles

First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.

John E. Wagner, MD, Akemi Ishida-Yamamoto, Ph.D., John A McGrath, Ph.D., Maria Hordinsky, M.D., Douglas R Keene, B.S., Mark Osborn, B.S., Troy Lund, MD, PhD, Michelle Dolan, Bruce R. Blazar, MD, Jakub Tolar, MD, PhD

Blood (2009) 114 (22): 660.

https://doi.org/10.1182/blood.V114.22.660.660

Published: 2009

NARROW

CD16-IL15-CD33 Trispecific Killer Engager (TriKE) Overcomes Cancer-Induced Immune Suppression and Induces Natural Killer Cell-Mediated Control of MDS and AML Via Enhanced Killing Kinetics

Continuous IL-15 Signaling Leads to Functional Exhaustion of Human Natural Killer Cells through Metabolic Changes That Alters Their In Vivo Anti-Tumor Activity

FANCN Hypomorphic Mutation Retains BRCA1 Binding Domain

Megatal, Crispr/Cas9, and Talen T-Cell Receptor Gene Editing

Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion

Outcomes after Donor Lymphocyte Infusion for Insufficient Donor Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders

Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Mitochondrial Haplotype As an Independent Predictor of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Optimized Cyclophosphamide (CY) Dosing in Combination with Fludarabine, TBI and ATG As Conditioning for Unrelated Donor Bone Marrow Transplantation (BMT) in Severe Aplastic Anemia (SAA): A Phase I/II Study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN)

Optimal Xenogeneic Adoptive Transfer of Human NK Cells: Fresh NK Cells and IL-15 Administration Are Superior to Frozen NK Cells and IL-2

Education and Cytokine Receptor Balance Play a Critical Role in Long Term Survival of the Most Differentiated Natural Killer (NK) Cells.

Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes

DNA Methylation Profile of Runx1 Regulatory Regions Is Correlated with Transition From Primitive to Definitive Hematopoietic Potential In Vitro and In Vivo

Dyskeratosis Congenita: Evaluation of Immune Status and Hematopoietic Stem Cell Transplantation. A Literature and EBMT Data Base Survey of 75 Patients,

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Bone Marrow Myeloid-Derived Suppressor Cells (MDSC) Inhibit Graft Versus Host Disease (GVHD) Via An Arginase-1 Dependant Mechanism That Is Upregulated by IL-13

Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Cerebral Variant Adrenoleukodystrophy: A Modern, Single-Institution Experience

Effect of Stem Cell Source From Unrelated Donors on Transplant Outcomes In Severe Aplastic Anemia (SAA): a Comparison of Unrelated Bone Marrow (BM) and Peripheral Blood Progenitor Cells (PBPC)

“Tasting the Microenvironment”: Human Bone Marrow Stromal Cells Have Microenvironment Chemosensory Capacity Via Taste Receptor Expression

First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only